Executive interview – Shield Therapeutics

Published on 25 March 2019

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom that listed on AIM in 2016. Its primary focus is the commercialisation of Feraccru, approved by the EMA for the treatment of iron deficiency, with or without anaemia. Commercialisation of Feraccru in key markets (ex US) is in the hands of distribution partners Norgine, AOP Orphan and Ewopharma.

In this video, the company’s CEO and co-founder Carl Sterritt introduces the company and Feraccru, discusses the recently announced positive top-line data from a Phase IIIb marketing study (AEGIS-H2H) and the commercialisation strategy for Feraccru in the US once a decision on regulatory approval is reached by the US FDA (PDUFA date of 27 July 2019).

Share this with friends and colleagues